Alzheimers Disease Clinical Trials in Chapel Hill, NC

About Alzheimers Disease Clinical Trials in Chapel Hill

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 14 alzheimers disease clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 3,963 participants. Research is being sponsored by Guerbet, University of Washington, University of North Carolina, Chapel Hill and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.